Robert Lutz
Consultant / Advisor chez ShangPharma Innovation, Inc.
Profil
Robert Lutz is currently an Executive-in-Residence at ShangPharma Innovation, Inc. He was previously a VP-Translational Research & Development at ImmunoGen, Inc. from 1992 to 2015.
He received a doctorate degree from Brandeis University in 1987 and an undergraduate degree from the University of New Hampshire in 1981.
Postes actifs de Robert Lutz
| Sociétés | Poste | Début |
|---|---|---|
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Consultant / Advisor | - |
Anciens postes connus de Robert Lutz
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | 01/04/2015 |
Formation de Robert Lutz
| University of New Hampshire | Undergraduate Degree |
| Brandeis University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
